Eosinophilic Fasciitis Clinical Trial
Official title:
Efficacy of High-Intensity Laser Therapy for the Management of Eosinophilic Fasciitis: A Case Report
NCT number | NCT05915585 |
Other study ID # | 010/012023 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | June 18, 2023 |
Est. completion date | July 20, 2023 |
Eosinophilic fasciitis (EF) is a rare musculoskeletal disorder characterized by inflammation and thickening of the fascia, leading to pain, stiffness, and functional impairment. Conventional treatment options include immunosuppressive medications, corticosteroids, and physical therapy. This case report will describe use of high-intensity laser therapy (HILT) using the Mectronic Exand MY high-intensity laser system in a patient with EF, highlighting its potential as an alternative or adjunct treatment option.
Status | Recruiting |
Enrollment | 1 |
Est. completion date | July 20, 2023 |
Est. primary completion date | July 19, 2023 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Patients diagnosed with Eosinophilic fasciitis. Exclusion Criteria: - a diagnosis unrelated to Eosinophilic fasciitis |
Country | Name | City | State |
---|---|---|---|
Egypt | Outpatient clinic of faculty of physical therapy, Ahram Canadian University | Al ?ayy Ath Thamin | Giza |
Lead Sponsor | Collaborator |
---|---|
Ahram Canadian University |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pain intensity via Numeric pain rating scale | Changes in pain intensity at baseline and 4 weeks | ||
Primary | Functional outcomes via Disabilities of the Arm, Shoulder and Hand questionnaire (DASH) | Changes in DASH at baseline and 4 weeks | ||
Primary | Quality of life via Short Form-36 Health Survey | Changes in Short Form-36 Health Survey at baseline and 4 weeks | ||
Primary | Adverse event | adverse events are recorded by the patient and therapist | 4 Weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT04305678 -
Mepolizumab for Eosinophilic Fasciitis
|
Phase 1 | |
Completed |
NCT04752397 -
The Influence of Extracorporeal Photopheresis on Skin Sclerosis
|